The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world survival outcomes and prognostic factors with adjuvant pembrolizumab for renal cell carcinoma.
 
Antonio Faieta
No Relationships to Disclose
 
Zuhair Majeed
No Relationships to Disclose
 
Edmund Folefac
No Relationships to Disclose
 
Paul Monk
Consulting or Advisory Role - Dendreon; Myovant Sciences; Pfizer/NCCN; Sanofi
Research Funding - Arvinas (Inst); Bayer (Inst); BioXCell (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); regeneron (Inst)
 
Ahmad Shabsigh
No Relationships to Disclose
 
Steven Clinton
Research Funding - American Cancer Society; American Institute for Cancer Research; Department of Defense-Prostate Cancer Research Program; NIH; The National Cattleman's Beef Association; United States Department of Agriculture
 
Eric Singer
Consulting or Advisory Role - Aura Biosciences; Ferring
Research Funding - Astellas Medivation
 
Amir Mortazavi
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Seagen (Inst)
 
Merve Hasanov
Honoraria - Curio Science (I)
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Eisai (I); Pfizer (I); Telix Pharmaceuticals (I)
 
Elshad Hasanov
Honoraria - Curio Science
Consulting or Advisory Role - Eisai; Pfizer; Telix Pharmaceuticals